Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

The user is seeking a topical minoxidil and finasteride combination without propylene glycol due to scalp irritation. They are looking for a supplier in the US.

A user shared their hair regrowth success using microneedling with a dermaroller every 6 days and minoxidil, recommending betadine (povidone-iodine) before microneedling to sterilize the scalp and enhance results. Another user noted the potential risks of iodine toxicity.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

The user experienced rapid diffuse hair thinning for five years despite no signs of AGA or miniaturization. They tried finasteride and oral minoxidil without success and have checked thyroid, iron, and vitamin D levels.

Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.

Diffuse thinning is often due to androgenetic alopecia, and DHT blockers like finasteride are recommended. Treatments mentioned include minoxidil, finasteride, dutasteride, and RU58841, with emphasis on starting early and using a holistic approach.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

User shares 6.5 months of progress using topical finasteride 0.1% and minoxidil 10%, along with lasercomb, dermaroller, Nizoral, scalp massager, and biotin. They seek feedback on their results.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

The user shared their 11-month hair regrowth journey using 0.83mg finasteride, Minoxidil twice daily, random derma rolling, and occasional Ketoconazole showers. They reported significant improvement, moving from a Norwood scale of 5.5 to around 2.5-3, and encouraged consistency for results.

Considering a hair transplant for diffuse thinning may harm existing follicles. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

The user experienced significant hair regrowth by returning to a regimen of 1mg oral finasteride daily and daily topical minoxidil after previously reducing their doses. They also emphasize maintaining energy and health through diet, exercise, and supplements.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

A user shared their progress after a 4,000-graft hair transplant, using finasteride (1.25 mg daily) and oral minoxidil (2.5 mg daily) for six months. They reported no side effects from the medication and noted significant improvement in hair density.

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

The post discusses using ImageJ software to objectively track hair regrowth progress. The user is treating Androgen alopecia with dutasteride and minoxidil.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

The conversation is about the struggles of dealing with diffuse thinning at a young age and the lack of significant improvement after using treatments like finasteride and minoxidil. Some suggest additional methods like derma rolling, microneedling, and hair fibers, while others share their own experiences and encourage persistence with treatment.

Verteporfin reduces scar tissue in hair transplants but doesn't significantly regrow hair follicles. More testing is needed to determine its effectiveness.

The conversation discusses the effectiveness of using finasteride alone versus combining it with minoxidil, ketoconazole, and microneedling for hair loss treatment. It also touches on the affordability and accessibility of hair transplants, with differing opinions on the financial feasibility of such procedures.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.